Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Operating Leases: 2021-2024

Historic Operating Leases for Kiniksa Pharmaceuticals International (KNSA) over the last 4 years, with Dec 2024 value amounting to $7.9 million.

  • Kiniksa Pharmaceuticals International's Operating Leases fell 18.01% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 18.01%. This contributed to the annual value of $7.9 million for FY2024, which is 21.42% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Operating Leases of $7.9 million as of FY2024, which was down 21.42% from $10.0 million recorded in FY2023.
  • In the past 5 years, Kiniksa Pharmaceuticals International's Operating Leases registered a high of $10.0 million during FY2023, and its lowest value of $2.6 million during FY2022.
  • Moreover, its 3-year median value for Operating Leases was $7.9 million (2024), whereas its average is $6.8 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Operating Leases soared by 282.16% in 2023 and then fell by 21.42% in 2024.
  • Over the past 4 years, Kiniksa Pharmaceuticals International's Operating Leases (Yearly) stood at $2.7 million in 2021, then dropped by 1.91% to $2.6 million in 2022, then soared by 282.16% to $10.0 million in 2023, then fell by 21.42% to $7.9 million in 2024.